Anesthesia and Cancer Study: Renal Cell Carcinoma

Not Applicable

Active, not recruiting

• Conditions: Renal Cell Carcinoma
• Interventions: Drug: Inhaled General Anesthetics; Drug: Propofol

• Registration Number: NCT04503148
• Lead Sponsor: Seoul National University Hospital

Brief Summary

This study investigates the influence of type of anesthesia on recurrence and survival of renal cell carcinoma in patients undergoing nephrectomy. The participants will be allocated to either the group receiving the total intravenous anesthesia (TIVA) using propofol or the group receiving the inhaled anesthetics, such as sevoflurane or desflurane.

Detailed Description

The effect of anesthesia on cancer recurrence and survival is controversial. According to some retrospective studies and preclinical studies, TIVA is suggested to be more favorable than inhalation anesthesia regarding cancer recurrence and survival after surgery. However, to our knowledge, there is no study which investigates the influence of type of anesthesia on recurrence of renal cell carcinoma after nephrectomy.

Study Timeline

• Study First Submitted: 2020-08-03
• Study First Submitted QC: 2020-08-03
• Study First Posted: 2020-08-07
• Study Start: 2020-09-22
• Primary Completion: 2022-12-22
• Status Verified: 2024-07
• Last Update Submitted: 2024-07-20
• Last Update Posted: 2024-07-23
• Study Completion: 2025-12-22

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 562

Inclusion Criteria

• Adult patients scheduled for elective nephrectomy due to renal cell carcinoma

Exclusion Criteria

• Emergency surgery
• Pregnancy
• Allergies to anesthetics
• Palliative surgery
• Refusal to participate in the study
• History of diagnosis or surgery for other cancer

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
inhalation group	Inhaled General Anesthetics	Patients receiving inhalation anesthesia using sevoflurane or desflurane
TIVA group	Propofol	Patients receiving the total intravenous anesthesia using propofol

Primary Outcome Measures

Name	Time	Method
five year metastasis-free survival	five year after surgery	five year metastasis-free survival

Secondary Outcome Measures

Name	Time	Method
one year survival	one year after surgery	survival rate regardless of recurrence
five year survival	five year after surgery	survival rate regardless of recurrence
one year metastasis-free survival	one years after surgery	one year metastasis-free survival
three year metastasis-free survival	three years after surgery	three year metastasis-free survival
three year survival	three year after surgery	survival rate regardless of recurrence

Trial Locations

Locations (1)

Seoul National University Hospital; 🇰🇷 Seoul, Korea, Republic of